Likely no new information presented for most of you; however, it is a good overview for individuals that are new to healthspan/life span optimization.
4 Likes
More Matt Kaeberlein … this time a focus on the Dog Aging Project:
2 Likes
I don’t follow Matt closely, but he expressed strong negative vehemence at the FDA for insisting that 2 proposed human clinical trials be done at daily transplant dosage levels versus weekly levels.
Not a promising forecast that good science on people will be done with rapamycin given the bureaucratic tendencies of the FDA.
5 Likes
I bet one proposed clinical trial is Dr. Jonathan An the Dentist … his research colleague at University of Washington… that wants to test periodontal gum disease… improvement with rapamycin dosing.
Link: Anti-aging drug holds promise for age-related oral diseases -Â UW School of Dentistry
That’s about as pissy as I have ever seen him. Lol.
It would be good to see the FDA’s reasoning on this. In any event this sort of thing can be challenged.
The really hard thing about trials, however, is that it is unlikely that there is a single solution to improving healthspan. Hence you need combinations. The best timing and dosing of those combinations is also likely to vary to some extent by the individual participating.
This is hard to fit in a standardised RCT.
1 Like